Relationship between serum IL-18 and VEGF levels in patients with prostate cancer

详细信息    查看全文

• 作者：Shaojun Nong (1)
  Yueping Zhang (1)
  Shujun Zhou (1)
  Wenguang Li (1)
  Limin Ma (1)
  You Wu (1)
  
• 关键词：interleukin ; 18 (IL ; 18) ; vascular endothelial growth factor (VEGF) ; prostate cancer
• 刊名：The Chinese-German Journal of Clinical Oncology
• 出版年：2010
• 出版时间：November 2010
• 年：2010
• 卷：9
• 期：11
• 页码：643-647
• 全文大小：248KB
• 参考文献：1. Cristi E, Perrone G, Toscano G, / et al. Tumour proliferation, angiogenesis, and ploidy status in human colon cancer. J Clin Pathol, 2005, 58: 1170鈥?174. CrossRef
  2. Mendoza L, Valcarcel M, Carrascal T, / et al. Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma etastasis. Cancer Res, 2004, 6: 304鈥?10. CrossRef
  3. Balkow S, Loser K, Krummen M, / et al. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. Exp Dermatol, 2009, 18:78鈥?7. CrossRef
  4. Park S, Cheon S, Cho D. The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol, 2007, 4: 329鈥?35.
  5. Khatri A, Husaini Y, Ow K, / et al. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res, 2009, 15: 2323鈥?334. CrossRef
  6. Delongchamps NB, Peyromaure M, Dinh-Xuan AT. Role of vascular endothelial growth factor in prostate cancer. Urology, 2006, 68:244鈥?48. CrossRef
  7. Kaushal V, Mukunyadzi P, Dennis RA, / et al. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin Cancer Res, 2005, 11: 584鈥?93.
  8. Carpini JD, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis, 2010, 13: 43鈥?8. CrossRef
  9. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol, 2001, 19: 1207鈥?225.
  10. Miyake H, Hara I, Yamanaka K, / et al. Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology, 1999, 53: 302鈥?07. CrossRef
  11. Werther K, Christensen IJ, Nielsen HJ, / et al. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer, 2002, 86: 417鈥?23. CrossRef
  12. Karayiannakis AJ, Syrigos KN, Polychronidis A, / et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg, 2002, 236: 37鈥?2. CrossRef
  13. Teknos TN, Cox C, Yoo S, / et al. Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck, 2002, 24: 1004鈥?011. CrossRef
  14. Cooper BC, Ritchie JM, Broghammer CL, / et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res, 2002, 8: 3193鈥?197.
  15. Catena R, Muniz-Medina V, Moralejo B, / et al. Increased expression of VEGF 121/VEGF 165鈥?89 ratio results in a significant enhancement of human prostate tumor angiogenesis. Inter J Cancer, 2007, 120: 2096鈥?109. CrossRef
  16. Kang JS, Bae SY, Kim HR, / et al. nterleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis, 2009, 30: 1987鈥?996. CrossRef
  17. Khalili-Azad T, Razmkhah M, Ghiam AF, / et al. Association of interleukin-18 gene promoter polymorphisms with breast cancer. Neoplasma, 2009, 56: 22鈥?5. CrossRef
  18. Samsami Dehaghani A, Shahriary K, Kashef MA, / et al. Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep, 2009, 36: 2393鈥?397. CrossRef
  19. Perrella O, Cuomo O, Sbreglia C, / et al. IL-18 and Interferon-gamma in HCV-related hepatocellular carcinoma: a model of interplay between immune status and cancer. J Biol Regul Homeost Agents, 2009, 23: 251鈥?58.
  20. Shaojun N, Duangai W, Caibin F, / et al. Clinical value of serum interleukin-18 in patients with prostate cancer. Chinese-German J Clin Oncol, 2007, 6: 574鈥?78. CrossRef
  21. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, / et al. Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterology, 2006, 12: 4473鈥?477.
  22. Yamamoto Y, Toi M, Kondo S, / et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res, 1996, 2: 821鈥?26.
  23. Hicklin DJ. Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 2005, 23:1011鈥?027. CrossRef
  24. Li H, Kantoff PW, Ma J, / et al. Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 2005, 14:1 557鈥?561.
  25. Peyromaure M, Goulvestre C, Fulla Y, / et al. Serum levels of vascular endothelial growth factor in patients undergoing prostate biopsy for suspicion of prostate cancer. Urology, 2005, 66: 687鈥?91. CrossRef
  26. Miyake H, Muramaki M, Kurahashi T, / et al. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol, 2010, 28: 145鈥?51.
  27. Tahir SA, Park S, Thompson TC. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol Ther, 2009, 8: 2286鈥?296. CrossRef
  28. Wong SY, Haack H, Crowley D, / et al. Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res, 2005, 65: 9789鈥?798. CrossRef
  29. Kitagawa Y, Dai J, Zhang J, / et al. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res, 2005, 65: 10921鈥?0929. CrossRef
  30. Han MY, Zheng S, Yu JM, / et al. Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity. J Zhejiang Univ (Science), 2004, 5: 472鈥?76. CrossRef
  31. Park CC, Morel JC, Amin MA, / et al. Evidence of IL-18 as a novel angiogenic mediator. J Immunol, 2001, 167: 1644鈥?653.
  32. Cao R, Farnebo J, Kurimoto M, / et al. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J, 1999, 13: 2195鈥?202.
  33. Jablonska E, Puzewska W, Grabowska Z, / et al. VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokines, 2005, 30: 93鈥?9. CrossRef
  34. Crohns M, Saarelainen S, Laine S, / et al. Poussa, Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival. Cytokine, 2010, 50: 30鈥?6. CrossRef
  35. Morel JC, Park CC, Zhu K, / et al. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chemistry, 2002, 277: 34679鈥?4691. CrossRef
  36. Cho ML, Jung YO, Moon YM, / et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunology Lett, 2006, 103: 159鈥?66. CrossRef
  37. Lee JK, Kim SH, Lewis EC, / et al. Differences in signaling pathways by IL-1beta and IL-18. Proc Nat Acad Sci U S A, 2004, 101: 8815鈥?820. CrossRef
  38. Nakahira M, Ahn HJ, Park WR, / et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by upregulating the binding activity of IL-18-induced activator protein 1. J Immunol, 2002, 168: 1146鈥?153.
  
• 作者单位：Shaojun Nong (1)
  Yueping Zhang (1)
  Shujun Zhou (1)
  Wenguang Li (1)
  Limin Ma (1)
  You Wu (1)
  
  1. Department of Urological Surgery, The Affiliated Hospital of Nantong University, Nantong, 226001, China
  

文摘

Objective The aim of our study was to analyze interleukin-18 (IL-18) and vascular endothelial growth factor (VEGF) serum levels in patients with prostate cancer before and after operation and the possible correlation between IL-18 and VEGF serum levels. Methods Serum IL-18 and VEGF levels were measured by enzyme-linked immunosorbent assay (ELISA) in 36 patients with prostate cancer before and after radical prostatectomy and in 25 healthy controls. Results Serum IL-18 and VEGF levels were significantly higher in patients with prostate cancer before operation with respect to healthy controls (P < 0.05), with a highly significant correlation between IL-18 and VEGF (R = 0.800, P = 0.017). It was significantly reduced in IL-18 and VEGF after operation. IL-18 and VEGF serum concentrations were correlated with the clinicalopathological status of patients with prostate cancer. Conclusion It is correlative with serum IL-18 and VEGF. Serum IL-18 and VEGF levels may be useful prognostic marker in patients with prostate cancer.